Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib

doi:10.3748/wjg.v20.i3.786

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 3

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7796)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-6) series.

Item

Count

PDF

567

WORD

316

HTML

3773

Figures (1-1)

290

Tables (1-6)

299

Sum=5245

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1242

Download

1309

Sum=2551

Jan 21, 2014 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (20)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Jan 21, 2014; 20(3): 786-794
Published online Jan 21, 2014. doi: 10.3748/wjg.v20.i3.786

Table 3 Changes in laboratory parameters at the beginning and the end of sorafenib treatment according to the reason of treatment interruption

			Bilirubin (mg/dL)	gGT (U/L)	ALP (U/L)	Platelets/mm³	INR	AST (U/L)	AFP (ng/mL)
Patients with treatment suspension due to progressive disease (n = 25; median treatment duration 19 wk)	Baseline	mean (SD) med (min-max)	1.3 (0.8)	192.5 (187.5)	173.8 (92.5)	143160 (83075.6)	1.18 (0.25)	66.5 (35.7)	3668.6 (8533.3)
	Baseline	mean (SD) med (min-max)	1.2 (0.2-3.5)	114 (41-648)	142 (64-436)	125000 (50000-337000)	1.10 (0.9-2.2)	66 (3.6-191)	18.8 (2.7-28136)
	End of treatment	mean (SD) median (min-max)	2.3 (1.7)	256.4 (276.8)	225.4 (196.3)	151360 (93196.4)	1.17 (0.26)	106.4 (97.8)	11060.4 (21903)
	End of treatment	mean (SD) median (min-max)	1.6 (0.3-6.4)	165 (20-1249)	182 (75-1048)	114000 (42000-426000)	1.1 (0.9-2.2)	71 (2-472)	83.4 (3.0-73434.5)
	Mann-Whitney test	P value	0.003	0.008	0.163	0.391	0.724	0.012	0.013
Patients with treatment suspension due to AEs (n = 19; median treatment duration 5 wk)	Baseline	mean (SD) med (min-max)	1.6 (0.7)	144.4 (107.4)	170 (83)	122125 (67280.4)	1.14 (0.92)	76.0 (38.6)	1739.0 (2841.1)
	Baseline	mean (SD) med (min-max)	1.4 (0.6-3.1)	123 (40-416)	159.5 (65-345)	102000 (35000-254000)	1.1 (1.0-1.3)	66.5 (27-188)	70.6 (1.6-6836.9)
	End of treatment	mean (SD) median (min-max)	2.9 (2.8)	168.3 (147.1)	218.8 (142.8)	135500 (75371.1)	1.14 (0.17)	91.1 (41.5)	2204.4 (4406.1)
	End of treatment	mean (SD) median (min-max)	2.3 (0.7-12.2)	121.5 (40-525)	183 (75-515)	123000 (37000-277000)	1.05 (1.0-1.4)	83.5 (27-153)	124.1 (2.1-14000)
	Mann-Whitney test	P value	0.029	0.441	0.051	0.147	0.891	0.125	0.333

gGT: Gamma-glutamyltranspeptidase; ALP: Alkaline phosphatase; AST: Aspartate transaminase; AFP: Alpha-fetoprotein; INR: International normalized ratio.

Citation: Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Costanzo FD, Marra F. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol 2014; 20(3): 786-794
URL: https://www.wjgnet.com/1007-9327/full/v20/i3/786.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i3.786